The BTLA–HVEM axis restricts CAR T cell efficacy in cancer
Puneeth Guruprasad(Parker Institute for Cancer Immunotherapy), Marco Ruella(Parker Institute for Cancer Immunotherapy), Jakub Svoboda(UPMC Hillman Cancer Center), Ositadimma Ugwuanyi(Hospital of the University of Pennsylvania), Kingsley Gideon Kumashie(Helmholtz Centre for Infection Research), Yoon Lee(Advanced Biomass R&D Center (South Korea)), Ruchi P. Patel(University of Pennsylvania), Linhui Chen(Hospital of the University of Pennsylvania), Alberto Carturan(Hospital of the University of Pennsylvania), Mathew G. Angelos(University of Pennsylvania), Hatcher J. Ballard(University of Pennsylvania), Jong-Seo Lee(Advanced Biomass R&D Center (South Korea)), Jaryse Harris(Hospital of the University of Pennsylvania), Guido Ghilardi(Hospital of the University of Pennsylvania), Maksim Shestov(University of Pennsylvania), Luca Paruzzo(Hospital of the University of Pennsylvania), Shane Kammerman, Laura A. Vella(Children's Hospital of Philadelphia), Olga Shestova(University of Pennsylvania), Jong Hyun Cho(Rutgers, The State University of New Jersey), Junho Chung(Cancer Research Institute), Patrizia Porazzi(Hospital of the University of Pennsylvania), C Sauter(Parker Institute for Cancer Immunotherapy), Jong Hoon Kim(Severance Hospital), Stephen J. Schuster(Hospital of the University of Pennsylvania), Audrey Bochi-Layec(University of Pennsylvania), Michael Wang(St. Joseph Health System), Shan Liu(University of Pennsylvania), Ki Hyun Kim(Chonnam National University Hwasun Hospital), Aasha Gupta(University of Pennsylvania), Seok Jae Albert Hong(University of Pennsylvania), Dongfang Liu(Rutgers, The State University of New Jersey), Yunlin Zhang(Hospital of the University of Pennsylvania), Ivan Cohen(Hospital of the University of Pennsylvania), Akshita Joshi(University of Pennsylvania), Yong Gu Lee(Parker Institute for Cancer Immunotherapy), Raymone Pajarillo(University of Pennsylvania), Jesse L. Rodriguez(University of Pennsylvania)
Cited by 41
Related Papers
Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications
|Science|2020|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
GABA-modulating bacteria of the human gut microbiota
|Nature Microbiology|2018|1.1k
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
|JAMA Oncology|2019|829